We used histology and longitudinal PET/CT imaging using the VAP-1-targeted [68Ga]Ga-DOTA-Siglec-9 to monitor the effect of FAP-IL2v treatment in the B16-FAP melanoma model, which comprises B16 cells recombinantly over-expressing murine FAP. This evidence concerns the gene FAP and melanoma.